Hyloris Pharmaceuticals SA
LSE:0AB6
Hyloris Pharmaceuticals SA
LSE:0AB6
Price:
5.6
EUR
-3.45%
Market Cap:
€1.5m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Hyloris Pharmaceuticals SA
LSE:0AB6
|
BE |
|
Adyen NV
F:1N8U
|
NL |
Income Statement
Earnings Waterfall
Hyloris Pharmaceuticals SA
Hyloris Pharmaceuticals SA
Income Statement
Hyloris Pharmaceuticals SA
Hyloris Pharmaceuticals SA
Currency: EUR
| Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||
| Interest Expense |
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
1
N/A
|
3
+233%
|
3
+6%
|
1
-73%
|
2
+68%
|
2
+38%
|
5
+143%
|
8
+66%
|
7
-13%
|
|
| Gross Profit | ||||||||||
| Cost of Revenue |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Gross Profit |
1
N/A
|
3
+250%
|
3
+6%
|
1
-75%
|
1
+70%
|
2
+45%
|
5
+147%
|
8
+67%
|
7
-14%
|
|
| Operating Income | ||||||||||
| Operating Expenses |
(11)
|
(13)
|
(10)
|
(12)
|
(19)
|
(18)
|
(18)
|
(15)
|
(13)
|
|
| Selling, General & Administrative |
(1)
|
(3)
|
(3)
|
(4)
|
(6)
|
(6)
|
(6)
|
(6)
|
(5)
|
|
| Research & Development |
(4)
|
(5)
|
(8)
|
(10)
|
(16)
|
(14)
|
(13)
|
(10)
|
(10)
|
|
| Other Operating Expenses |
(5)
|
(5)
|
0
|
1
|
3
|
2
|
1
|
1
|
2
|
|
| Operating Income |
(10)
N/A
|
(10)
-6%
|
(7)
+29%
|
(12)
-57%
|
(18)
-52%
|
(16)
+10%
|
(13)
+19%
|
(6)
+50%
|
(6)
+11%
|
|
| Pre-Tax Income | ||||||||||
| Interest Income Expense |
(2)
|
(1)
|
(0)
|
(0)
|
0
|
1
|
1
|
(0)
|
(1)
|
|
| Non-Reccuring Items |
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
0
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
0
|
(0)
|
(0)
|
|
| Pre-Tax Income |
(12)
N/A
|
(11)
+3%
|
(8)
+29%
|
(12)
-49%
|
(18)
-47%
|
(15)
+12%
|
(12)
+20%
|
(6)
+48%
|
(7)
-4%
|
|
| Net Income | ||||||||||
| Tax Provision |
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(12)
|
(12)
|
(8)
|
(12)
|
(18)
|
(15)
|
(12)
|
(6)
|
(6)
|
|
| Net Income (Common) |
(12)
N/A
|
(12)
+1%
|
(8)
+28%
|
(12)
-44%
|
(18)
-47%
|
(15)
+12%
|
(12)
+20%
|
(6)
+48%
|
(6)
-1%
|
|
| EPS (Diluted) |
-0.45
N/A
|
-0.45
N/A
|
-0.32
+29%
|
-0.44
-38%
|
-0.65
-48%
|
-0.55
+15%
|
-0.42
+24%
|
-0.23
+45%
|
-0.23
N/A
|
|
Switch to:
Switch to:
See Also
Discover More
